With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
With the ISIS-1 trial, Dr Peter Sleight and his team at Oxford changed the approach to cardiovascular research. Join Dr Robert Califf as he talks to Dr Sleight about his journey from London to San Francisco to Oxford and finally to Italy, where he discovered the music of the heart.
Drs Bonhoeffer and Kovac discuss size, sterility, location, presence of multidisciplinary teams, and imaging techniques - issues to consider in creating an ideal lab that can also adapt to future technologies and developments.
Exactly three years after the DES firestorm ignited the World Congress of Cardiology in Barcelona, heartwire's Shelley Wood sifts through the ashes with Drs Tony Gershlick, Christian Spaulding, and Renu Virmani in a discussion on DES safety and what we've learned since September 2006.
Dr Robert Califf sits down with Drs Alfred Bove, Jack Lewin, and Clyde Yancy and AHA CEO Nancy Brown to talk about the ACC and the AHA and their role in the debate on healthcare reform.
Join Drs Valentin Fuster, William E Boden, and George D Dangas as they discuss the results, plus the evolution of therapy over the last forty years, the mechanisms of coronary artery disease progression in diabetic patients, and what is perhaps one of the most fundamental problems in the field: that patients today are still not treated to target with best medical therapy.
Join Dr Robert Califf for a probing and personal interview with Dr Steve Nissen, about his activist days at the University of Michigan and the development of IVUS, to how he ended up at the Cleveland Clinic and what he thinks about the future of medicine in America.
With the global trend leaning toward increased use of transradial access, our international panel reports on standard practice at their respective institutions and the key issues that influence it such as bleeding, access-site complications, stroke risk, patient mobility, and operator experience. Join Drs Kandzari (US), Feres (Brazil), Le May (Canada), and Steg (France) for this thoughtful and practical discussion.
Join Drs Valentin Fuster, Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf as they unravel the STICH trial and debate the lessons learned from PROTECT-AF in Part 1 of the Cardiology Show. In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.
Drs Gregg Stone and William Weintraub discuss the misconceptions some patients have about the benefits and purpose of elective PCI and what can be done to rectify them in a candid discussion moderated by heartwire's Shelley Wood.
As theheart.org enters its 10th year join editor-in-chief, Dr Eric Topol, and his guests for a second look at the top news from the past decade. Throughout the coming months, we'll revisit the most important story from each of the last 10 years and ask: How has practice been affected? With time and perspective, what has changed and what have we learned?
Join Drs Raymond Gibbons, Antonio Colombo, William Boden, Ph Gabriel Steg, and Valentin Fuster for another look at the COURAGE trial, as they discuss the latest data and talk about where things stand now on the larger controversy.
Dr Melissa Walton-Shirley talks to Drs Ph Gabriel Steg and Raymond Gibbons about the differences in STEMI care on both sides of the Atlantic and what US cardiologists can learn from their colleagues in Europe.
Drs Antonio Colombo and Renu Virmani talk about the one-year results of the SYNTAX trial, the importance of understanding registries, and the complex issue of clopidogrel duration with drug-eluting stents in a discussion moderated by heartwire journalist Shelley Wood.
Dr Gregg Stone talks to Drs Keith Fox and Gilles Montalescot about the implications of the DES meta-analysis and the interventional cardiology late-breaking trials presented at the joint SCAI-ACC i2 2008 Scientific Sessions.
Drs Keith Fox and Gregg Stone go into the details of this practice-changing trial as they address concerns about acute stent thrombosis and talk about ways to improve outcomes, in a discussion moderated by Dr James Ferguson.
Debate continues over drug-eluting stentsDrs Gregg Stone and Renu Virmani share their hopes and concerns for PCI and drug-eluting stents as they weigh in on the COURAGE nuclear substudy and the latest registry data on DES vs BMS in a discussion moderated by heartwire journalist Shelley Wood.
SYNTAX and MAIN-COMPARE suggest a role for PCI in subsets of patients with left main disease; however, in current ACC/AHA guidelines this remains a class III indication. Dr. Turco chairs a roundtable with interventionalists Drs Kandzari and Park and surgeon Dr Sabik.
Since BARI, CABG has been the gold standard for patients with diabetes and multivessel disease. However, SYNTAX suggests an increasing role for PCI and BARI 2D highlights the importance of optimal medical therapy. Dr. Boden leads a multidisciplinary discussion with Drs. Holmes and Taggart.
Dr. Dean Kereiakes leads an international panel of experts, Drs. Meredith, Banning, and Hermiller, as they discuss fascinating developments in stent and polymer technology and design their "dream stent."
How do the results of the SYNTAX trial impact clinical practice now? Join Drs. Banning and Hill as they present a complex case taken directly from the SYNTAX trial and discuss how new data will impact their choice of treatment, and listen to an overview of the trial presented by Dr. William Wijns.
The PARTNER and PAVIS trials of transcatheter aortic valve implementation will include inoperable or very high-surgical-risk patients. In Europe, where the devices have been approved for a few years, the technology is being expanded to lesser-risk patients. Interventionalist Dr Jeffrey Popma discusses the selection of patients with surgeon Dr Mathew Williams.
Transcatheter aortic valve implantation (TAVI) has been approved in Europe since 2007, whereas these devices are just entering large-scale research trials in the United States. Dr. Popma leads a panel discussion with European interventionalist Dr. Eberhard Grube and surgeon Dr. Neil Moat on their experiences with TAVI.
How do drug-eluting stents compare? Our panel of experts, Drs. Stone, Kereiakes, Serruys, and Windecker discuss the late-breaking trials at TCT 2009 of DES vs DES.
Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.